D3465C00001 (TULIP)
Research type
Research Study
Full title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus
IRAS ID
296584
Contact name
David D'cruz (Add Apostrophe to Email)
Contact email
Sponsor organisation
AstraZeneca
Eudract number
2020-004529-22
Clinicaltrials.gov Identifier
101849, IND number
Duration of Study in the UK
2 years, 8 months, 28 days
Research summary
We are doing this study to learn more about an investigational medication called anifrolumab for people with moderate to severe SLE (Systemic lupus erythematosus), also known as ‘lupus’. The main purpose of this study is to look at whether the investigational medication works to improve disease symptoms in people with moderate to severe SLE. The study will also look at how safe the investigational medication is and how the body handles taking it. We are also doing this study to better understand the treatment of moderate to severe SLE and associated health problems.
REC name
London - Brighton & Sussex Research Ethics Committee
REC reference
21/LO/0559
Date of REC Opinion
18 Feb 2022
REC opinion
Further Information Favourable Opinion